Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 3732: Peripheral pharmacodynamic activity of epcoritamab as monotherapy and in combination with rituximab + lenalidomide in patients with follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HSHan SiQingdao UniversityJZJimin ZhangTongji UniversityMWMonica Wielgos-BonvalletGenmab (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Si et al. (2024) studied this question.

synapsesocial.com/papers/68e72ce8b6db6435876a6ffbhttps://doi.org/10.1158/1538-7445.am2024-3732
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PO-003: Peripheral blood and tumor tissue biomarkers associated with epcoritamab response in patients with relapsed or refractory diffuse large B-cell lymphoma: Data from the dose-expansion cohort of the phase 1/2 EPCORE NHL-1 trial (NCT03625037)2024 · 2 citations
  2. 2primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  3. 3Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma2025 · 14 citations
  4. 4EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.2024 · 7 citations
  5. 5Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial2025 · 29 citations